advanced solid tumors
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Patient age of 18-70 years - Patients with advanced cancer planned to receive chemotherapy - Life expectancy of at least 12 weeks - Disease with a malignant lesion of at least 1,5 cm diameter within the chest as measured by Response Evaluation Criteria in Solid Tumors (RECIST) - Performance status Karnofsky index > 60 % - Hemoglobin > 6.0 mmol/l - Written informed consent
Exclusion criteria
Exclusion criteria: - Previous treatment with taxanes - Claustrophobia - Pregnant or lactating patients - Patients having metal implants (e.g. pacemakers) - Due to the fact that docetaxel is a substrate for P-glycoprotein (P-gp), patients using P-gp drugs like digoxin, cyclosporin, amiodarone, steroids, quinidine, colchicine, etoposide, anti-estrogens will be excluded - Use of coumarin derivatives or inhibitors of thrombocyte aggregation - Concurrent treatment with experimental drugs - Participation in a clinical trial with any investigational drug within 30 days prior to study entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics of [11C]docetaxel | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparison venous versus arterial sampling and comparison of an on-line plasma curve with an IDIF 2. Reproducibility of [11C]docetaxel PET measurements 3. Biodistribution of [11C]docetaxel. | — |
Countries
Netherlands
Outcome results
None listed